Literature DB >> 3092653

Effect of a single oral dose of enprostil on gastric secretion and gastrin release. Studies in healthy volunteers and patients with pernicious anemia.

N Buchanan, G Laferla, J Hearns, K D Buchanan, G P Crean, K E McColl.   

Abstract

In healthy human volunteers, a single oral dose of enprostil (35 micrograms) inhibited basal gastric acid output by a mean of 71 percent, pentagastrin-stimulated output by 46 percent, sham-meal-stimulated output by 48 percent, and histamine-stimulated output by 16 percent. In each case, there was a reduction in both the volume and acidity of the gastric juice. Pepsin output was unchanged. Although enprostil increased the gastric pH, it did not induce basal or post-prandial hypergastrinemia. In patients with hypergastrinemia secondary to achlorhydria, enprostil lowered the basal gastrin level and reduced or abolished the post-prandial gastrin rise in a dose-related fashion. Enprostil reduces basal and stimulated gastric acid secretion and inhibits gastrin release.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092653     DOI: 10.1016/s0002-9343(86)80009-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients.

Authors:  A Tari; M Hamada; T Kamiyasu; K Sumii; K Haruma; M Inoue; S Kishimoto; G Kajiyama; J H Walsh
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

2.  Inhibitory action of enprostil (4,5-dehydro-16-phenoxy-17,18,19,20-tetranor-PGE2) on tetra-gastrin stimulated acid secretion in human subjects.

Authors:  M Moriga; M Aono; H Narusawa; Y Kohli; T Kato; G Kajiyama; M Inoue; A Miyoshi
Journal:  Gastroenterol Jpn       Date:  1989-04

Review 3.  The significance of gastrin in the pathogenesis and therapy of peptic ulcer disease.

Authors:  C B Lamers
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  A US multicenter study of enprostil 35 micrograms twice daily for treatment of prepyloric, pyloric channel, and duodenal bulb ulcers. Enprostil Study Group.

Authors:  T T Schubert; J A Frizzell; P B Meier; R I Cano; K E Schwartz
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

5.  Effect of two-week treatment with enprostil (35 micrograms twice a day) on 24-hour serum gastrin levels.

Authors:  C Florent; C Cogoni; M Joubert; B Desaint
Journal:  Dig Dis Sci       Date:  1990-11       Impact factor: 3.199

6.  Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

7.  Effect of synthetic prostaglandin E2 analog enprostil on omeprazole-induced hypergastrinemia and hyperpepsinogenemia.

Authors:  J L Meijer; L F Crobach; J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

Review 8.  Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.

Authors:  K L Goa; J P Monk
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.